Helix Biopharma Corp. Antibody-Urease Conjugates for Diagnostic and Therapeutic Use
Summary
The European Patent Office granted Patent EP2984170A1 to Helix Biopharma Corp. for antibody-urease conjugates for diagnostic and therapeutic purposes. The patent, with inventor Chao Heman, covers compositions classified under A61K 47/68, A61P 35/00, C07K 16/32, C12N 9/80, and C12N 9/96. The designated states include all EU member states and extension countries.
What changed
The European Patent Office granted Patent EP2984170A1 to Helix Biopharma Corp. for antibody-urease conjugates for diagnostic and therapeutic applications. The patent covers compositions for therapeutic use, particularly in cancer treatment, and is effective across all designated EU member states and extension countries.
This patent grant gives Helix Biopharma exclusive rights in Europe to develop and commercialize products based on antibody-urease conjugate technology. Biotech and pharmaceutical companies engaged in antibody conjugate research, immunotherapy development, or diagnostic assay development should review this patent for potential freedom-to-operate implications and consider whether licensing discussions or design-around strategies are warranted.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF ANTIBODY-UREASE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
Publication EP2984170A1 Kind: A1 Apr 08, 2026
Applicants
Helix Biopharma Corp.
Inventors
CHAO, Heman
IPC Classifications
A61K 47/68 20170101AFI20250912BHEP A61P 35/00 20060101ALI20250912BHEP C07K 16/32 20060101ALN20250912BHEP C12N 9/80 20060101ALN20250912BHEP C12N 9/96 20060101ALN20250912BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.